Compare RYTM & TXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYTM | TXG |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.0B |
| IPO Year | 2017 | 2019 |
| Metric | RYTM | TXG |
|---|---|---|
| Price | $115.63 | $52.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 15 |
| Target Price | ★ $131.14 | $20.25 |
| AVG Volume (30 Days) | 640.7K | ★ 2.8M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.34 | ★ 76.97 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $245,893,000.00 |
| Revenue This Year | $55.34 | N/A |
| Revenue Next Year | $86.06 | $7.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 68.06 |
| 52 Week Low | $74.50 | $11.17 |
| 52 Week High | $122.20 | $50.34 |
| Indicator | RYTM | TXG |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 55.55 |
| Support Level | $98.76 | $16.11 |
| Resistance Level | $113.03 | N/A |
| Average True Range (ATR) | 4.84 | 2.78 |
| MACD | 0.15 | -0.55 |
| Stochastic Oscillator | 98.64 | 43.64 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).